Caroline Dierickx

Van Herk Investments BV (VHI) is the private equity investment arm of the Van Herk Groep BV, based in Rotterdam. The parent firm was established in the 1950s as a family business with a focus on real estate investments. VHI invests in listed and unlisted firms across diverse sectors primarily in The Netherlands.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Van Herk Groep BV provides investment services to the real estate, energy, and life science sectors. The company was founded by Aat van Herk and is headquartered in Rotterdam, the Netherlands.

Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium.